Valeant is sued over Philidor ties, alleged racketeering

Adjust Comment Print

The plaintiffs are seeking a jury trial and unspecified damages over $5 million (U.S.) on behalf of themselves and other similar third-party payers between January 2, 2013 and October 30, 2015. The stock's Dividend stands at 0 and Dividend Yield stands at 0 Percent. Equities research analysts predict that Valeant Pharmaceuticals International will post $6.54 EPS for the current year. Valeant Pharmaceuticals International, Inc. represents Distance from 200-Day simple Moving Average as -42.26 Percent.

The lawsuit states, "Valeant was able to implement many of these price hikes because it was simultaneously steering patients and physicians away from generic equivalents and toward Valeant-branded drugs through its secretly controlled network of pharmacies led by Philidor".

Valeant Pharmaceuticals International (NYSE:VRX): On Fridays trading session, Opening price of the stock was $31.48 with an intraday high of $31.839. The stock is now trading at Distance from 20-Day Simple Moving Average of 17.79% while its Distance from 50-Day Simple Moving Average is 29.45 Percent. The difference between the actual EPS of last year's corresponding period and the mean estimate of $0.26 comes to 23.81%. The share price is now at -20.03% for the past six months. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The stock was purchased at an average cost of $24.65 per share, with a total value of $98,600.00. Following the completion of the transaction, the chief executive officer now owns 2,442,199 shares of the company's stock, valued at $59,785,031.52. This is an excellent indicator of heavy volume accumulation and distribution from institutional investors. Acrospire Investment Management LLC acquired a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $108,000. Now shares have been rated as "Buy" from 8 Analysts.

More news: Turkey warns of more strikes if Syrian Kurds don't retreat

Several other equities analysts have also recently weighed in on the company.

During last 3 month it remained at 8.48%. According to these analysts, the Low Revenue Estimate for Valeant Pharmaceuticals International, 2.44 Billion and the High Revenue Estimate is 2.55 Billion.

During the 52-week period, the peak price level of the share was observed at $322.68; this is higher price of share and down price level of the share was seen at $195.50; this is lower price at which share is traded. Finally, Wells Fargo & Co. reissued a sell rating and set a $19.50 price target (down from $27.50) on shares of Valeant Pharmaceuticals International in a report on Tuesday, June 7th. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).